{"id":8840,"date":"2025-06-26T06:16:52","date_gmt":"2025-06-26T11:16:52","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=8840"},"modified":"2025-07-13T15:08:42","modified_gmt":"2025-07-13T20:08:42","slug":"nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u65b0\u305f\u306a\u5148\u898b\u6027\u306e\u3042\u308b\u8aee\u554f\u59d4\u54e1\u4f1a\u3068\u5171\u306b\u3001\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\u306b\u304a\u3051\u308b\u60a3\u8005\u4e2d\u5fc3\u306e\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3092\u63a8\u9032"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"8840\" class=\"elementor elementor-8840\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-65279c3f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"65279c3f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4b40c268\" data-id=\"4b40c268\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-76485331 elementor-widget elementor-widget-text-editor\" data-id=\"76485331\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"col-sm-8 col-vcenter col-xs-12\"><div class=\"col-sm-8 col-vcenter col-xs-12\"><div class=\"col-sm-8 col-vcenter col-xs-12\"><div class=\"col-sm-8 col-vcenter col-xs-12\"><div class=\"col-sm-8 col-vcenter col-xs-12\"><h3 style=\"text-align: center;\">\u00a0<\/h3><\/div><div class=\"col-sm-4 col-xs-12 col-vcenter\"><div class=\"image logo logo-wrapper\" data-src=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-asset-type=\"photo\" data-asset-label=\"Logo\" data-download-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg\" data-tweet-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-pinterest-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-linkedin-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-facebook-share-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-twitter-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=twitter\" data-facebook-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=facebook\" data-pinterest-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-linkedin-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=linkedin\"><p><span class=\"legendSpanClass\"><span class=\"xn-location\">\u30c0\u30e9\u30b9<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">2025\u5e746\u670826\u65e5 <\/span><\/span>&#8212;\u00a0<a href=\"http:\/\/nanostherapeutics.com\/ja\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>, \u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u3088\u308b\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u306b\u82e6\u3057\u3080\u60a3\u8005\u306e\u305f\u3081\u306e\u65b0\u898f\u907a\u4f1d\u5b50\u975e\u4f9d\u5b58\u578b\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u3068\u5546\u696d\u5316\u306b\u53d6\u308a\u7d44\u3080\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308b \u306f\u672c\u65e5\u3001\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/who-we-are\/#vac\" target=\"_blank\" rel=\"nofollow noopener\">\u30d3\u30b8\u30e7\u30ca\u30ea\u30fc\u8aee\u554f\u59d4\u54e1\u4f1a\uff08VAC\uff09<\/a>\u00a0&#8211; a group of renowned experts in retina treatment and commercialization.<\/p><p class=\"prntaj\">The VAC will serve as a strategic and mission-aligned team that informs Nanoscope&#8217;s scientific, clinical, and community-facing efforts.\u00a0<b><i>\u305d\u306e\u4f7f\u547d\u306f\u3001\u60a3\u8005\u30b1\u30a2\u3092\u5411\u4e0a\u3055\u305b\u3001\u533b\u5e2b\u3068\u306e\u771f\u646f\u306a\u95a2\u308f\u308a\u3092\u4fc3\u9032\u3057\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u304a\u3088\u3073\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\u3092\u60a3\u3046\u4eba\u3005\u306b\u9769\u65b0\u7684\u306a\u6cbb\u7642\u6cd5\u3092\u6700\u521d\u306b\u63d0\u4f9b\u3059\u308b\u305f\u3081\u306e\u9053\u7b4b\u3092\u63cf\u304f\u3053\u3068\u3067\u3059\u3002.<\/i><\/b><\/p><p class=\"prntaj\">&#8220;This is more than just a committee \u2014 it represents a clear declaration of our unwavering commitment to the patients we serve and the mission in which we believe,&#8221; said\u00a0<span class=\"xn-person\">\u30b9\u30e9\u30cb\u30e3\u30fb\u30d0\u30bf\u30c1\u30e3\u30ea\u30e4<\/span>, co-founder and CEO of Nanoscope Therapeutics. &#8220;At Nanoscope we&#8217;re building the future of retinal care with our eyes wide open, guided by those who truly understand the lives of the patients we are committed to helping.&#8221;<\/p><p class=\"prntaj\">MCO-010 is the most advanced clinical-stage optogenetic therapy in development for RP. Using Nanoscope&#8217;s proprietary Multi-Characteristic Opsin (MCO), MCO-010 is the first optogenetic investigational therapy to demonstrate potential vision restoration in patients with severe vision loss in clinical trials.<\/p><p class=\"prntaj\">&#8220;What sets MCO-010 apart is not only its scientific advances, but its real-world accessibility,&#8221; added Bhattacharya. &#8220;It&#8217;s designed to be delivered as a single, in-office injection\u2014without the need for genetic testing, surgery, or ongoing maintenance.&#8221;<\/p><p>\u306e\u00a0<b>VAC\u306e\u8b70\u9577\u306f\u3001\u30de\u30cd\u30fc\u30b8\u30f3\u30b0\u30c7\u30a3\u30ec\u30af\u30bf\u30fc\u306eSriniVas Sadda\u6c0f\u304c\u52d9\u3081\u308b\u3002<\/b>.\u3001A\u3002.\u00a0<span class=\"xn-person\">\u30ec\u30a4\u30fb\u30a2\u30fc\u30d0\u30a4\u30f3\u30fb\u30b8\u30e5\u30cb\u30a2.<\/span>, \u533b\u5b66\u535a\u58eb\u3001\u81e8\u5e8a\u773c\u79d1\u5b66\u306e\u5bc4\u4ed8\u8b1b\u5ea7\u6559\u6388\u3001\u00a0<span class=\"xn-org\">\u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5927\u5b66\u30ed\u30b5\u30f3\u30bc\u30eb\u30b9\u6821<\/span>\u00a0\u30c7\u30d3\u30c3\u30c9\u30fb\u30b2\u30d5\u30a3\u30f3\u533b\u79d1\u5927\u5b66\u304a\u3088\u3073\u30c9\u30d8\u30cb\u30fc\u773c\u79d1\u7814\u7a76\u6240\u3002.<\/p><p class=\"prntaj\">&#8220;As retina specialists, we face a desperate need to change the conversation about blindness with our patients \u2014 from one of inevitability to one of possibility,&#8221; said Dr. Sadda. &#8220;I&#8217;m honored to be part of a team that believes the status quo is not set in stone, and that restoration of vision is not a dream \u2014 it&#8217;s a goal within reach.&#8221;<\/p><p>\u30b5\u30c3\u30c0\u535a\u58eb\u306e\u4ed6\u306b\u3001VAC\u306e\u30e1\u30f3\u30d0\u30fc\u306b\u306f\u4ee5\u4e0b\u306e\u4eba\u7269\u304c\u542b\u307e\u308c\u307e\u3059\u3002<\/p><ul type=\"disc\"><li><b><span class=\"xn-person\">\u30a2\u30ec\u30f3\u30fb\u30db\u30fc<\/span>\u533b\u5b66\u535a\u58eb\u3001\u00a0<\/b>\u773c\u79d1\u5b66\u6559\u6388,\u00a0<span class=\"xn-org\">\u30c8\u30fc\u30de\u30b9\u30fb\u30b8\u30a7\u30d5\u30a1\u30fc\u30bd\u30f3\u5927\u5b66<\/span>\u00a0\u30a6\u30a3\u30eb\u30ba\u773c\u79d1\u75c5\u9662\u7db2\u819c\u7814\u7a76\u90e8\u9577\u3002\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306e\u6700\u9ad8\u533b\u7642\u9867\u554f\u3002<\/li><li><b><span class=\"xn-person\">\u30d4\u30fc\u30bf\u30fc\u30fb\u30ab\u30a4\u30b6\u30fc<\/span>\u533b\u5b66\u535a\u58eb\u3001\u00a0<\/b>\u30af\u30ea\u30fc\u30d6\u30e9\u30f3\u30c9\u30fb\u30af\u30ea\u30cb\u30c3\u30af\u30fb\u30e9\u30fc\u30ca\u30fc\u533b\u79d1\u5927\u5b66\u773c\u79d1\u5b66\u6559\u6388\u3001\u30b3\u30fc\u30eb\u773c\u79d1\u7814\u7a76\u6240\u30c1\u30a7\u30a4\u30cb\u30fc\u5bb6\u5bc4\u4ed8\u8b1b\u5ea7\u773c\u79d1\u5b66\u7814\u7a76\u62c5\u5f53<\/li><li><b><span class=\"xn-person\">\u30af\u30ea\u30b9\u30c6\u30a3\u30f3\u30fb\u30b1\u30a4<\/span>, \u533b\u5b66\u535a\u58eb<\/b>.\u3001\u81e8\u5e8a\u7814\u7a76\u304a\u3088\u3073\u7db2\u819c\u907a\u4f1d\u5b66\u30c7\u30a3\u30ec\u30af\u30bf\u30fc\u3001\u785d\u5b50\u4f53\u7db2\u819c\u30a2\u30bd\u30b7\u30a8\u30a4\u30c4\u00a0<span class=\"xn-location\">\u30b2\u30a4\u30f3\u30ba\u30d3\u30eb<\/span><\/li><li><b><span class=\"xn-person\">\u30a2\u30eb\u30b7\u30e3\u30c9\u30fb\u30cf\u30ca\u30cb<\/span>, \u533b\u5b66\u535a\u58eb\u3001\u4fee\u58eb\u3001,\u00a0<\/b>\u81e8\u5e8a\u6559\u6388\u3001,\u00a0<span class=\"xn-org\">\u30cd\u30d0\u30c0\u5927\u5b66\u30ea\u30ce\u6821<\/span>\u00a0\u533b\u5b66\u90e8\u304a\u3088\u3073\u30b7\u30a8\u30e9\u30fb\u30a2\u30a4\u30fb\u30a2\u30bd\u30b7\u30a8\u30a4\u30c4\u81e8\u5e8a\u7814\u7a76\u90e8\u9577<\/li><li><b><span class=\"xn-person\">\u30f4\u30a3\u30cb\u30c3\u30c8\u30fb\u30de\u30cf\u30b8\u30e3\u30f3<\/span>, \u533b\u5b66\u535a\u58eb\u3001\u54f2\u5b66\u535a\u58eb,\u00a0<\/b>\u773c\u79d1\u5b66\u6559\u6388,\u00a0<span class=\"xn-org\">\u30b9\u30bf\u30f3\u30d5\u30a9\u30fc\u30c9\u5927\u5b66<\/span>\u00a0\u307e\u305f\u3001\u30d0\u30a4\u30a2\u30fc\u30ba\u773c\u79d1\u7814\u7a76\u6240\u306e\u7814\u7a76\u62c5\u5f53\u526f\u90e8\u9577\u517c\u5206\u5b50\u5916\u79d1\u30d7\u30ed\u30b0\u30e9\u30e0\u8cac\u4efb\u8005\u3082\u52d9\u3081\u308b\u3002<\/li><li><b>\u30b8\u30e7\u30eb\u30c7\u30a3\u30fb\u30e2\u30cd\u30b9\u533b\u5e2b\u3001\u533b\u5b66\u535a\u58eb\u3001,\u00a0<\/b>\u30de\u30ad\u30e5\u30e9\u7814\u7a76\u6240\u6240\u9577\u3001,\u00a0<span class=\"xn-location\">\u30d0\u30eb\u30bb\u30ed\u30ca<\/span><\/li><li><b><span class=\"xn-person\">\u30de\u30fc\u30af\u30fb\u30da\u30cd\u30b7<\/span>, \u533b\u5b66\u535a\u58eb\u3001\u54f2\u5b66\u535a\u58eb,\u00a0<\/b>Adjunct Professor of Ophthalmology, Casey Eye Institute, Oregon Health &amp; Science University and Director, Inherited Retinal Degenerations Division, Retina Foundation<\/li><\/ul><p>\u8a73\u3057\u3044\u7d4c\u6b74\u306b\u3064\u3044\u3066\u306f\u3001\u4ee5\u4e0b\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/who-we-are\/#vac\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/nanostherapeutics.com\/who-we-are\/#vac<\/a><\/p><p class=\"prntaj\">The formation of the VAC reflects Nanoscope&#8217;s\u00a0belief that bringing meaningful innovation to patients begins with partnership and continues with action, to bring back the light of hope to the millions of patients across the world suffering from retinal degeneration.<\/p><p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u3067\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u308b\u3002RESTORE\u30d5\u30a7\u30fc\u30ba\u3067\u306e\u826f\u597d\u306a\u7d50\u679c\u3092\u53d7\u3051\u3066\u3001\u00a0<span class=\"xn-money\">2b<\/span>\/3 \u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306b\u5bfe\u3059\u308b\u591a\u65bd\u8a2d\u5171\u540c\u3001\u7121\u4f5c\u70ba\u5316\u3001\u4e8c\u91cd\u76f2\u691c\u3001\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>\uff09FDA\u3078\u306eBLA\u7533\u8acb\u306f\u9806\u6b21\u958b\u59cb\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3042\u308b\u3002\u00a0<span class=\"xn-chron\">2025\u5e746\u6708<\/span>. \u627f\u8a8d\u3055\u308c\u308c\u3070\u3001MCO-010\u306f\u907a\u4f1d\u5b50\u691c\u67fb\u3092\u5fc5\u8981\u3068\u305b\u305a\u3001\u8a3a\u7642\u6240\u30671\u56de\u6ce8\u5c04\u3059\u308b\u3060\u3051\u3067\u6295\u4e0e\u3067\u304d\u308b\u305f\u3081\u3001RP\u60a3\u8005\u306e\u6a19\u6e96\u6cbb\u7642\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u3002\u540c\u793e\u306f\u307e\u305f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\u306b\u5bfe\u3059\u308bMCO-010\u306e\u7b2c2\u76f8\u81e8\u5e8a\u8a66\u9a13STARLIGHT\u3067\u3082\u6709\u671b\u306a\u7d50\u679c\u3092\u793a\u3057\u3066\u3044\u308b\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\uff09\u305d\u3057\u3066\u3001\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30d5\u30a7\u30fc\u30ba3\u767b\u9332\u8a66\u9a13<\/a>\u00a02025\u5e74\u306b\u767a\u58f2\u4e88\u5b9a\u306eMCO-010\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3068\u810a\u9ac4\u6027\u7b4b\u840e\u7e2e\u75c7\uff08SD\uff09\u306e\u4e21\u65b9\u3067FDA\u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u3068\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u524d\u81e8\u5e8a\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u306f\u3001IND\u7533\u8acb\u306b\u5411\u3051\u305f\u7814\u7a76\u6bb5\u968e\u306b\u3042\u308b\u30ec\u30fc\u30d0\u30fc\u5148\u5929\u6027\u9ed2\u5185\u969c\uff08LCA\uff09\u306e\u307b\u304b\u3001\u5730\u56f3\u72b6\u840e\u7e2e\u75c7\uff08GA\uff09\u306b\u5bfe\u3059\u308bIND\u7533\u8acb\u6e96\u5099\u6bb5\u968e\u306e\u85ac\u5264\u304c\u542b\u307e\u308c\u3066\u3044\u307e\u3059\u3002.<\/p><p><b>\u63a5\u89e6\uff1a<\/b><br class=\"dnr\" \/>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p><p>\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p><\/div><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>\u00a0 DALLAS,\u00a0June 26, 2025 &#8212;\u00a0Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering severe vision loss from\u00a0retinal degenerative diseases, today announced the formation of its\u00a0Visionary Advisory Committee (VAC)\u00a0&#8211; a group of renowned experts in retina treatment and commercialization. The VAC will serve as a strategic and mission-aligned team that informs Nanoscope&#8217;s scientific, clinical, and community-facing efforts.\u00a0Its mission: to elevate the care of patients, foster authentic engagement with physicians, and help chart the path to delivering a transformative therapy first to people living with retinitis pigmentosa (RP) and Stargardt disease (SD). &#8220;This is more than just a committee \u2014 it represents a clear [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":8841,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-8840","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-26T11:16:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-13T20:08:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee\",\"datePublished\":\"2025-06-26T11:16:52+00:00\",\"dateModified\":\"2025-07-13T20:08:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\"},\"wordCount\":727,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\",\"name\":\"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg\",\"datePublished\":\"2025-06-26T11:16:52+00:00\",\"dateModified\":\"2025-07-13T20:08:42+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u65b0\u305f\u306a\u5148\u898b\u6027\u306e\u3042\u308b\u8aee\u554f\u59d4\u54e1\u4f1a\u3092\u8a2d\u7acb\u3057\u3001\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\u306b\u304a\u3051\u308b\u60a3\u8005\u4e2d\u5fc3\u306e\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3092\u63a8\u9032 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-06-26T11:16:52+00:00","article_modified_time":"2025-07-13T20:08:42+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee","datePublished":"2025-06-26T11:16:52+00:00","dateModified":"2025-07-13T20:08:42+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/"},"wordCount":727,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","url":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u65b0\u305f\u306a\u5148\u898b\u6027\u306e\u3042\u308b\u8aee\u554f\u59d4\u54e1\u4f1a\u3092\u8a2d\u7acb\u3057\u3001\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\u306b\u304a\u3051\u308b\u60a3\u8005\u4e2d\u5fc3\u306e\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3092\u63a8\u9032 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg","datePublished":"2025-06-26T11:16:52+00:00","dateModified":"2025-07-13T20:08:42+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/8840","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=8840"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/8840\/revisions"}],"predecessor-version":[{"id":9068,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/8840\/revisions\/9068"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/8841"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=8840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=8840"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=8840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}